千叶蓍(Achillea millefolium)在经前综合征(PMS)管理中的作用:一项双盲、随机、安慰剂对照试验OA
Effect of Achillea millefolium in the management of premenstrual syndrome(PMS):A double-blind,randomized placebo-controlled trial
背景:经前综合征(PMS)是一种周期性疾病,会影响女性的身体、情绪及社交健康.传统疗法可能引发不良反应,因此亟需更安全的替代方案.千叶蓍(Achillea millefolium)在尤纳尼医学中被记载具有抗炎、抗痉挛、镇痛及益脑等作用,传统用于维持情绪稳定及辅助治疗妇科疾病.目的:研究旨在通过一项随机、双盲、安慰剂对照临床试验,评估千叶蓍在经前综合征女性患者中的疗效和安全性,并与安慰剂进行比较.方法:该项双盲、随机、安慰剂对照临床试验在印度Karnataka邦Vijayapura市的Luqman乌纳尼医学院医院及研究中心的妇产科学系(Ilm al-Qabālat Amrād-i Niswān)开展,针对50 名患有PMS的18至40岁女性开展.报告遵循CONSORT 2025指南.在50名符合条件的患者中,有6名被排除,44名参与者被随机分为两组,其中22名分配至试验组,22名分配至对照组.试验组受试者服用千叶蓍(500 mg,每日三次,每次两粒,从月经周期的第21天至下一次周期的第3天),而对照组则按照相同的给药方案服用外观相同的安慰剂.两种干预措施均连续进行两个周期.共有4名受试者(每组各2名)失访,最终对完成研究的40名受试者进行符合方案分析.主要终点为PMS症状的减轻程度,采用PMTS-OR量表进行评估;次要结局包括通过视觉模拟量表(VAS)测量的腹痛变化.统计分析采用配对t检验和独立样本Z检验,P<0.05视为具有统计学意义.研究结果表明,与安慰剂组相比,试验组的经前期综合征症状和腹痛显著减轻.安全性评估和不良事件监测表明,该干预措施耐受性良好.该试验于2024年8月12日在印度临床试验注册中心完成注册后启动(注册号:CTRI/2024/07/071615,注册链接:https://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=112188&EncHid=24056.11844&modid=1&compid=19).结果:完成治疗方案后,千叶蓍组的PMTS-OR平均评分显著降低(P<0.001),而安慰剂组未见明显改善(P>0.05).两组间的差异表明,千叶蓍在缓解经前综合征症状方面具有明显的治疗优势.同样,试验组的平均VAS显著下降(P<0.001),而对照组未观察到显著变化.研究期间未报告任何不良事件.结论:千叶蓍在改善经前综合征的躯体、心理及行为表现方面具有显著效果,从而提升了整体生活质量.研究结果表明,千叶蓍可作为治疗经前综合征的一种安全、有效且经济实惠的尤纳尼疗法.
Background:Premenstrual syndrome(PMS)is a cyclical condition that affects women's physical,emotional,and social well-being.Conventional therapies may cause adverse effects,creating a need for safer options.Achillea millefolium,described in Unani medicine for its anti-inflammatory,antispasmodic,analgesic,and brain-tonic properties,is traditionally used to support emotional stability and gynaecological disorders. Objective:This study aims to evaluates A.millefolium's efficacy and safety compared with placebo in women with PMS through a randomized,doubleblind,placebo-controlled clinical trial. Methods:This double-blind,randomized,placebo-controlled clinical trial was conducted on 50 women aged 18-40 years presenting with PMS at the Department of Ilm al-Qabalat Amrad-i Niswan,Luqman Unani Medi-cal College Hospital and Research Centre,Vijayapura,Karnataka,India.This report follows the CONSORT 2025 guidelines.Out of 50 eligible patients,6 were excluded and 44 participants were randomized into two groups,with 22 allocated to the test group and 22 to the control group.Participants in the test group received A.mille-folium(500 mg,two capsules thrice daily from the 21st day of the menstrual cycle to the 3rd day of the next cycle),while the control group received an identical placebo according to the same regimen.Both interventions were administered for two consecutive cycles.Four participants(two from each group)were lost to follow-up,and the final analysis as per-protocol analysis was conducted on 40 participants who completed the study.The primary endpoint was reduction in PMS symptoms,assessed using the PMTS-OR scale,while secondary outcomes included changes in abdominal pain measured by the visual analogue scale(VAS).Statistical analysis was performed using paired and unpaired t-tests,with P<0.05 considered statistically significant.The findings demonstrated a signif-icant reduction in PMS symptoms and abdominal pain in the test group compared to the placebo group.Safety assessments and adverse event monitoring indicated that the intervention was well tolerated.The trial was started after registration with the Clinical Trials Registry of India CTRI/2024/07/071615 on August 12th 2024(URL:https://ctri.nic.in/Clinicaltrials/rmaindet.php?trialid=112188&EncHid=24056.11844&modid=1&compid=19). Results:After completion of the treatment protocol,the A.millefolium group demonstrated a significant reduction in mean PMTS-OR scores(P<0.001),whereas the placebo group showed no meaningful improvement(P>0.05).The between-group difference indicated a clear therapeutic advantage of A.millefolium in alleviating PMS symptoms.Similarly,mean VAS scores declined markedly in the test group(P<0.001),with no significant change observed in the control group.No adverse events were reported during the study period. Conclusion:A.millefolium demonstrated significant improvement in the physical,psychological,and behavioural manifestations of PMS,thereby enhancing overall quality of life.These findings suggest that A.millefolium may serve as a safe,effective,and affordable Unani therapeutic option for the management of PMS.
Shafa Ara Anjum;Nikhat Kausar Inamdar;Syeda Fatima Zohra;Shaikh Saba Naaz Nasir Ahmed;Pathan Sana Afroz;Tabassum Kudchi;Shazia Parveen Farooqui
Department of Niswan wa Qabalat(OBG),Luqman Unani Medical College Hospital and Research Centre,Naubag,Vijayapura 586101,Karnataka,IndiaDepartment of Niswan wa Qabalat(OBG),Luqman Unani Medical College Hospital and Research Centre,Naubag,Vijayapura 586101,Karnataka,IndiaDepartment of Niswan wa Qabalat(OBG),Luqman Unani Medical College Hospital and Research Centre,Naubag,Vijayapura 586101,Karnataka,IndiaDepartment of Niswan wa Qabalat(OBG),Luqman Unani Medical College Hospital and Research Centre,Naubag,Vijayapura 586101,Karnataka,IndiaDepartment of Niswan wa Qabalat(OBG),Luqman Unani Medical College Hospital and Research Centre,Naubag,Vijayapura 586101,Karnataka,IndiaDepartment of Niswan wa Qabalat(OBG),Luqman Unani Medical College Hospital and Research Centre,Naubag,Vijayapura 586101,Karnataka,IndiaClinical Research Department,Regional Research Institute of Unani Medicine,Chennai 600013,Tamil Nadu,India
千叶蓍Achillea millefolium经前综合征PMTS-OR
Achillea millefoliumPMSPMTS-OR
《临床传统医学和药理学(英文)》 2026 (2)
49-59,11
评论